Comedians such as Gilda Radney and Madeline Kohn, Oscar-winning actresses such as Loretta Young and Sandy Dennis, singers Laura NRO and Dinah Shore, actor Pierce Brosnan's wife Cassandra Harris, actress Jessica Tansy, former Connecticut governor Ella Grassy and Martin Luther King's wife Coretta Scott King died on ovarian cancer. It's not just celebrities, politicians or movie stars who have been affected by ovarian cancer. One in 55 women in the US is at risk of ovarian cancer. The American Cancer Society estimates that about 22,000 new cases of ovarian cancer will be diagnosed. More than 16,000 women die because the symptoms are often subtle, and her doctor did not recognize the symptoms early enough. It is the leading cause of death from gynecological malignancies and the fifth leading cause of cancer death in women.
Silent and undetected cancer often spreads beyond the ovary or ovaries to the abdominal cavity or, in the final stage, to other body organs such as the liver or lungs. Family physicians often fail to correctly diagnose the "Silent Killer" until it is too late. Last August, researchers at the University of California, Davis reported that 40 percent of women told their doctors about their symptoms up to a year before they were properly diagnosed. A British survey found that 75 percent of family doctors believed that symptoms were only present in advanced stages of cancer. By the time women are diagnosed with ovarian cancer, 40 to 50 percent of patients are at an advanced stage, where there is little hope of survival.
Less than half of women diagnosed with ovarian cancer survive five years. About 10 to 14 percent live more than five years after diagnosis. Their selection was limited, mainly reserved for variants of chemotherapy drugs or a new way of administering the drug. The general ''public'' is often unaware of the side effects that ovarian cancer patients suffer during chemotherapy. In mid-March, the U.S. Food and Drug Administration criticized the safety profile of Eli Lilly's Gemma for ovarian cancer patients, saying the 2.8-month increase in survival seen in studies of patients taking the drug was not enough to offset the increased toxicity of the treatment, which included anemia. Neutropenia (blood disorder) and thrombocytopenia (reduced number of platelets in the blood). Currently, used first-line treatments for ovarian cancer patients include cisplatin with associated side effects such as nerve, kidney and/or ear damage, carboxylating (adverse effects: nerve damage in arms and/or legs, joint pain and/or thrombocytopenia) patients (neurotoxicity) or cephalad, with side effects that include irreversible bone marrow failure, bone marrow suppression.
A woman affected by ovarian cancer first faces surgery, then chemotherapy. The recent widespread press heralding a new development in the treatment of ovarian cancer, intra-abdominal or intraperitoneal chemotherapy, is just that: more chemotherapy. The "belly bath," as some TV reporters have dubbed it, has been widely praised because the treatment can extend life by about 16 months more than "regular" chemotherapy. The results were first published in the prestigious New England Journal of Medicine in December 2005. Most news reports failed to mention that only 40 percent of women treated with belly baths were able to complete all six cycles. Why? Treatment consists of infusions of patients and cisplatin (see side effects in the previous paragraph). According to Dr. According to Robert Edwards, director of research at many Women's Gynecologic Cancer in Pittsburgh, Many women don't feel well enough to work for the duration of intra-abdominal (therapy). Some patients, like Cindy Pakalnis of Marshall, Pennsylvania, called the treatment "debilitating."
An unsolved problem of chemotherapy is the reduction of "quality of life". Although some life extension has been shown, the patient's life is getting worse. Many patients struggle with balancing the loss of quality of life with the rigors of therapy. Researchers are actively pursuing new directions that may one day provide new hope for the ovarian cancer patient. A University of Minnesota research study suggested the use of thalidomide, which would be used in conjunction with chemotherapy, as a prospective means of increasing the likelihood of remission. Minnesota's cancer researcher Dr. Levi Downs explained: “It prevents the tumor from forming new blood vessels. Without new blood vessels, the tumor can't feed enough new cells, so the cancer can't grow.” His randomized trial was small with only 65 patients (only 28 took thalidomide), and more tests will certainly be needed.
New hope for ovarian cancer patients?
One promising technology that has been developed in the last decade is Ova Rex
good
You must be logged in to post a comment.